About This Trial
Evaluating duration of protection and need for revaccination with approved RSV vaccine.
Primary Endpoints
- Efficacy against RSV-LRTD at Season 3
- Immunogenicity persistence
Latest Update
February 2026
Season 2 efficacy of 67% against RSV-LRTD maintained. Single dose may provide multi-season protection.